{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:02Z","timestamp":1790173322925,"version":"4.1.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Duchenne muscular dystrophy (DMD) is a progressive disabling X-linked recessive disorder that causes gradual and irreversible loss of muscle, resulting in early death. The corticosteroids prednisone\/prednisolone and deflazacort are used to treat DMD as the standard of care; however, only deflazacort is FDA approved for DMD. The novel atypical corticosteroid vamorolone is being investigated for treatment of DMD. We compared the pharmaceutical properties as well as the efficacy and safety of the three corticosteroids across multiple doses in the B10-mdx DMD mouse model. Pharmacokinetic studies in the mouse and evaluation of p-glycoprotein (P-gP) efflux in a cellular system demonstrated that vamorolone is not a strong P-gp substrate resulting in measurable central nervous system (CNS) exposure in the mouse. In contrast, deflazacort and prednisolone are strong P-gp substrates. All three corticosteroids showed efficacy, but also side effects at efficacious doses. After dosing mdx mice for two weeks, all three corticosteroids induced changes in gene expression in the liver and the muscle, but prednisolone and vamorolone induced more changes in the brain than did deflazacort. Both prednisolone and vamorolone induced depression-like behavior. All three corticosteroids reduced endogenous corticosterone levels, increased glucose levels, and reduced osteocalcin levels. Using micro-computed tomography, femur bone density was decreased, reaching significance with prednisolone. The results of these studies indicate that efficacious doses of vamorolone, are associated with similar side effects as seen with other corticosteroids. Further, because vamorolone is not a strong P-gp substrate, vamorolone distributes into the CNS increasing the potential CNS side-effects.<\/jats:p>","DOI":"10.1093\/hmg\/ddad173","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T19:52:58Z","timestamp":1697053978000},"page":"211-223","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models"],"prefix":"10.1093","volume":"33","author":[{"given":"Grace","family":"Liu","sequence":"first","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lipari","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mollin","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9276-175X","authenticated-orcid":false,"given":"Stephen","family":"Jung","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Teplova","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Li","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqing","family":"Ying","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"More","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lennox","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Yeh","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McGann","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Choon","family":"Moon","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cari","family":"Rice","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Huarte","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gruszka","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balmiki","family":"Ray","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-8876","authenticated-orcid":false,"given":"Elizabeth","family":"Goodwin","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Buckendahl","sequence":"additional","affiliation":[{"name":"Rutgers University, Molecular Imaging Center , 41 Gordon Road, Piscataway, NJ 08854, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yurkow","sequence":"additional","affiliation":[{"name":"Rutgers University, Molecular Imaging Center , 41 Gordon Road, Piscataway, NJ 08854, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Braughton","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Narasimhan","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Welch","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Voronin","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-8096","authenticated-orcid":false,"given":"Marla","family":"Weetall","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc. , 100 Corporate Court, South Plainfield, NJ 07080, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"2024012109544066300_ref1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","article-title":"Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis","volume":"17","author":"Salari","year":"2022","journal-title":"J Orthop Surg Res"},{"key":"2024012109544066300_ref2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2024012109544066300_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of Duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatr Neurol"},{"key":"2024012109544066300_ref4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"2024012109544066300_ref5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J Med Genet"},{"key":"2024012109544066300_ref6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.nmd.2007.03.002","article-title":"Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival","volume":"17","author":"Eagle","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"2024012109544066300_ref7","first-page":"121","article-title":"Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol"},{"key":"2024012109544066300_ref8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jpeds.2012.03.020","article-title":"Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation","volume":"161","author":"Pane","year":"2012","journal-title":"J Pediatr"},{"key":"2024012109544066300_ref9","doi-asserted-by":"crossref","first-page":"e1597","DOI":"10.1212\/WNL.0000000000008363","article-title":"Relationships between DMD mutations and neurodevelopment in dystrophinopathy","volume":"93","author":"Thangarajh","year":"2019","journal-title":"Neurology"},{"key":"2024012109544066300_ref10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development Subcommittee of the American Academy of neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"key":"2024012109544066300_ref11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"key":"2024012109544066300_ref12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"2024012109544066300_ref13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3233\/JND-210776","article-title":"Comparing Deflazacort and prednisone in Duchenne muscular dystrophy","volume":"9","author":"Biggar","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"2024012109544066300_ref14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/mus.23304","article-title":"Corticosteroids and Duchenne muscular dystrophy: does earlier treatment really matter?","volume":"45","author":"McDonald","year":"2012","journal-title":"Muscle Nerve"},{"key":"2024012109544066300_ref15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JND-221575","article-title":"Functional and clinical outcomes associated with steroid treatment among non-ambulatory patients with Duchenne muscular dystrophy","volume":"10","author":"McDonald","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"2024012109544066300_ref16","first-page":"CD003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2024012109544066300_ref17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MED.0000000000000456","article-title":"Growth, pubertal development, and skeletal health in boys with Duchenne muscular dystrophy","volume":"26","author":"Ward","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2024012109544066300_ref18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better?","volume":"16","author":"Kourakis","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2024012109544066300_ref19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1176\/appi.ajp.2014.13091264","article-title":"Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects","volume":"171","author":"Judd","year":"2014","journal-title":"Am J Psychiatry"},{"key":"2024012109544066300_ref20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/diagnostics13030337","article-title":"Recent updates on corticosteroid-induced neuropsychiatric disorders and theranostic advancements through gene editing tools","volume":"13","author":"Singh","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2024012109544066300_ref21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"2024012109544066300_ref22","doi-asserted-by":"crossref","first-page":"24285","DOI":"10.1073\/pnas.2006890117","article-title":"Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment","volume":"117","author":"Liu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012109544066300_ref23","doi-asserted-by":"crossref","first-page":"e201800186","DOI":"10.26508\/lsa.201800186","article-title":"Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy","volume":"2","author":"Heier","year":"2019","journal-title":"Life Sci Alliance"},{"key":"2024012109544066300_ref24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol Med"},{"key":"2024012109544066300_ref25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","article-title":"Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes","volume":"134","author":"Hoffman","year":"2018","journal-title":"Steroids"},{"key":"2024012109544066300_ref26","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"2024012109544066300_ref27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"key":"2024012109544066300_ref28","doi-asserted-by":"crossref","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024012109544066300_ref29","doi-asserted-by":"crossref","first-page":"1107474","DOI":"10.3389\/fneur.2023.1107474","article-title":"Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis","volume":"14","author":"Elhalag","year":"2023","journal-title":"Front Neurol"},{"key":"2024012109544066300_ref30","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"2024012109544066300_ref31","doi-asserted-by":"crossref","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"key":"2024012109544066300_ref32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/096368970000900411","article-title":"Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy","volume":"9","author":"Anderson","year":"2000","journal-title":"Cell Transplant"},{"key":"2024012109544066300_ref33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2007.12.005","article-title":"A mouse model of depression induced by repeated corticosterone injections","volume":"581","author":"Zhao","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2024012109544066300_ref34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pnpbp.2009.10.018","article-title":"Prednisolone causes anxiety- and depression-like behaviors and altered expression of apoptotic genes in mice hippocampus","volume":"34","author":"Kajiyama","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2024012109544066300_ref35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/npp.2015.235","article-title":"Gene-stress-epigenetic regulation of FKBP5: clinical and translational implications","volume":"41","author":"Zannas","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"2024012109544066300_ref36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.mp.4000536","article-title":"Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways","volume":"4","author":"Frisch","year":"1999","journal-title":"Mol Psychiatry"},{"key":"2024012109544066300_ref37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.biopsych.2005.01.030","article-title":"The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis","volume":"57","author":"L\u00f3pez Le\u00f3n","year":"2005","journal-title":"Biol Psychiatry"},{"key":"2024012109544066300_ref38","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0002-9343(81)90363-6","article-title":"Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis","volume":"71","author":"Shoenfeld","year":"1981","journal-title":"Am J Med"},{"key":"2024012109544066300_ref39","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.3390\/ijms19124090","article-title":"How glucocorticoids affect the neutrophil life","volume":"19","author":"Ronchetti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2024012109544066300_ref40","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ajem.2016.07.003","article-title":"Inhaled corticosteroids increase blood neutrophil count by decreasing the expression of neutrophil adhesion molecules Mac-1 and L-selectin","volume":"34","author":"Pasternak","year":"2016","journal-title":"Am J Emerg Med"},{"key":"2024012109544066300_ref41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00421-020-04593-1","article-title":"Changes in plasma hydroxyproline and plasma cell-free DNA concentrations after higher- versus lower-intensity eccentric cycling","volume":"121","author":"Mavropalias","year":"2021","journal-title":"Eur J Appl Physiol"},{"key":"2024012109544066300_ref42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/mus.25015","article-title":"Muscle damage, metabolism, and oxidative stress in mdx mice: impact of aerobic running","volume":"54","author":"Schill","year":"2016","journal-title":"Muscle Nerve"},{"key":"2024012109544066300_ref43","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1172\/JCI96636","article-title":"Glucocorticoid receptor dimers control intestinal STAT1 and TNF-induced inflammation in mice","volume":"128","author":"Ballegeer","year":"2018","journal-title":"J Clin Invest"},{"key":"2024012109544066300_ref44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1677\/joe.0.1750251","article-title":"The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone","volume":"175","author":"Karssen","year":"2002","journal-title":"J Endocrinol"},{"key":"2024012109544066300_ref45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.1987.5.2.202","article-title":"Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia","volume":"5","author":"Balis","year":"1987","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2024012109544066300_ref46","doi-asserted-by":"crossref","first-page":"107161","DOI":"10.1016\/j.isci.2023.107161","article-title":"Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice","volume":"26","author":"McCormack","year":"2023","journal-title":"iScience"},{"key":"2024012109544066300_ref47","first-page":"497","article-title":"Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients","volume":"43","author":"Cotton","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"2024012109544066300_ref48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"2024012109544066300_ref49","doi-asserted-by":"crossref","first-page":"9366","DOI":"10.18632\/oncotarget.14070","article-title":"Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor","volume":"8","author":"Wells","year":"2017","journal-title":"Oncotarget"},{"key":"2024012109544066300_ref50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"key":"2024012109544066300_ref51","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2217\/cer-2021-0018","article-title":"Meta-analyses of deflazacort versus prednisone\/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy","volume":"10","author":"Shieh","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2024012109544066300_ref52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh","year":"2018","journal-title":"Muscle Nerve"},{"key":"2024012109544066300_ref53","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"2024012109544066300_ref54","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"2024012109544066300_ref55","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1073\/pnas.85.12.4486","article-title":"A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells","volume":"85","author":"Pastan","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012109544066300_ref56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2024012109544066300_ref57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddad173\/52799471\/ddad173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/33\/3\/211\/56290015\/ddad173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/33\/3\/211\/56290015\/ddad173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T09:55:09Z","timestamp":1705830909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/33\/3\/211\/7306829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,11]]},"published-print":{"date-parts":[[2024,1,20]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddad173","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,10,11]]}}}